introduct
non
invas
posit
pressur
ventil
nippv
first
line
treatment
hypercapn
acut
respiratori
failur
arf
secondari
copd
exacerb
select
patient
limit
data
exist
support
use
fiberopt
bronchoscopi
fob
clinic
set
aim
studi
assess
role
fob
nippv
patient
decompens
copd
acut
exacerb
method
studi
random
prospect
case
control
pilot
studi
carri
patient
admit
critic
care
unit
alexandria
univers
hospit
egypt
suffer
hypercapn
arf
secondari
copd
exacerb
kelli
matthay
score
patient
receiv
nippv
patient
divid
randomli
equal
group
group
case
patient
subject
addit
intervent
earli
fob
first
h
admiss
group
ii
control
patient
receiv
convent
treatment
nippv
outcom
paramet
measur
chang
abg
data
durat
nippv
rate
success
icu
stay
mortal
well
safeti
fob
possibl
complic
result
signific
differ
detect
group
regard
baselin
characterist
seriou
complic
happen
fob
oxygen
desatur
happen
patient
tachycardia
patient
group
patient
success
wean
nippv
versu
patient
group
ii
p
total
durat
nippv
h
group
versu
h
group
ii
p
length
icu
stay
day
group
versu
day
group
ii
p
patient
die
group
versu
patient
group
ii
p
conclus
earli
applic
fob
nippv
patient
arf
due
copd
exacerb
shown
safe
signific
improv
outcom
patient
underw
fob
notic
term
improv
abg
data
shorter
durat
nippv
higher
percentag
success
shorter
icu
stay
signific
differ
detect
mortal
american
thorac
societi
european
respiratori
societi
british
thorac
societi
defin
copd
use
slightli
differ
word
approach
past
yearsth
global
initi
chronic
obstruct
lung
diseas
gold
report
produc
nation
heart
lung
blood
institut
nhlbi
world
health
organ
defin
copd
prevent
treatabl
diseas
signific
extrapulmonari
effect
may
contribut
sever
individu
patient
pulmonari
compon
character
airflow
limit
fulli
revers
airflow
limit
usual
progress
associ
abnorm
inflammatori
respons
lung
noxiou
particl
gase
global
initi
chronic
obstruct
lung
diseas
gold
report
produc
nation
heart
lung
blood
institut
nhlbi
world
health
organ
defin
exacerb
chronic
obstruct
pulmonari
diseas
copd
acut
increas
symptom
beyond
normal
daytoday
variat
gener
includ
acut
increas
one
follow
cardin
symptom
cough
increas
frequenc
sever
sputum
product
increas
volum
andor
chang
charact
dyspnea
increas
estim
percent
exacerb
due
respiratori
infect
mostli
bacteri
like
haemophilu
influenza
moraxella
catarrhali
streptococcu
pneumonia
pseudomona
aeruginosa
enterobacteriacea
viral
like
rhinovirus
influenza
parainfluenza
coronaviru
adenoviru
percent
due
environment
pollut
percent
unknown
etiolog
copd
exacerb
unknown
etiolog
may
relat
medic
condit
myocardi
ischemia
heart
failur
aspir
pulmonari
embol
patient
copd
present
hospit
acut
worsen
dyspnea
evalu
potenti
altern
diagnos
heart
failur
pulmonari
thromboembol
pneumonia
illustr
autopsi
studi
patient
copd
die
within
h
admiss
copd
exacerb
primari
caus
death
heart
failur
pneumonia
pulmonari
thromboembol
copd
percent
respect
noninvas
posit
pressur
ventil
nippv
refer
mechan
ventil
deliv
noninvas
interfac
face
mask
nasal
mask
nasal
prong
comfort
allow
expector
eat
speech
prevent
rebreath
full
face
mask
face
mask
gener
prefer
nasal
mask
nasal
prong
initi
niv
sever
reason
patient
acut
respiratori
failur
mouth
breather
therefor
niv
deliv
nasal
mask
result
larg
air
leak
mouth
wors
outcom
nasal
air
passag
offer
signific
resist
airflow
mitig
benefici
effect
nippv
low
level
posit
airway
pressur
use
two
princip
form
use
pressur
support
ventil
psv
bilevel
posit
airway
pressur
bipap
psv
common
mode
chosen
clinician
want
maxim
patient
comfort
synchroni
provid
posit
airway
pressur
respiratori
cycl
bipap
offer
pressur
biphas
manner
higher
pressur
inspir
expir
studi
patient
obstruct
lung
diseas
indic
lowlevel
cpap
offset
detriment
effect
autoposit
endexpiratori
pressur
caus
ga
trap
alveoli
end
expir
decreas
inspiratori
work
breath
addit
inspiratori
pressur
support
cpap
bipap
gener
improv
tidal
volum
proport
amount
pressur
appli
cpap
bipap
use
altern
intub
patient
varieti
respiratori
condit
includ
congest
heart
failur
pulmonari
edema
copd
avoid
complic
associ
endotrach
intub
improv
numer
clinic
outcom
prefer
method
ventilatori
support
mani
patient
acut
exacerb
copd
complic
hypercapn
acidosi
nippv
physiolog
benefit
respiratori
mechan
measur
initi
nippv
demonstr
decreas
respiratori
rate
increas
tidal
volum
increas
minut
ventil
addit
arteri
oxygen
tension
tend
increas
decreas
pressur
support
level
increas
patient
respiratori
rate
breath
per
min
respiratori
rate
indic
inspiratori
effort
reduc
reason
level
howev
expiratori
effort
patient
copd
may
increas
pressur
support
increas
make
select
optim
pressur
support
level
difficult
flexibl
fiberopt
bronchoscopi
fob
becom
indispens
tool
optim
manag
intens
care
unit
icu
patient
diagnost
therapeut
goal
safeti
use
welltrain
hand
appropri
precaut
led
increas
use
even
unstabl
mechan
ventil
patient
current
rigid
bronchoscop
often
use
except
manag
massiv
hemoptysi
remov
tracheobronchi
foreign
bodi
laser
photoresect
obstruct
endobronchi
tumour
dilat
tracheobronchi
strictur
placement
airway
stent
bronchoalveolar
lavag
bal
fob
wedg
subsegment
bronchu
multipl
aliquot
ml
salin
instil
lung
segment
withdrawn
suction
centrifug
bal
fluid
stain
opportunist
pathogen
cultur
although
ml
consid
maximum
recent
literatur
demonstr
lavag
volum
ml
well
toler
patient
eat
drink
anyth
h
procedur
also
tri
avoid
aspirin
ibuprofen
bloodthin
drug
procedur
procedur
gag
reflex
return
howev
patient
eat
drink
anyth
test
gag
reflex
return
place
spoon
back
tongu
second
light
pressur
patient
gag
wait
min
tri
aim
work
assess
role
earli
fiberopt
bronchoscopi
non
invas
ventil
acut
exacerb
copd
patient
term
effect
safeti
prospect
case
control
studi
carri
patient
suffer
hypercapn
acut
respiratori
failur
result
acut
exacerb
chronic
obstruct
pulmonari
diseas
copd
receiv
non
invas
mechan
ventil
admit
consecut
critic
care
unit
alexandria
univers
main
hospit
patient
divid
two
group
group
case
patient
receiv
convent
medic
treatment
plu
earli
fiberopt
bronchoscopi
non
invas
ventil
group
ii
control
patient
receiv
convent
medic
treatment
noninvas
ventil
copd
patient
met
follow
criteria
breath
oxygen
via
venturi
mask
ph
less
paco
mmhg
b
pao
fio
ratio
less
c
dyspnea
rest
respiratori
rate
rr
breathsmin
use
accessori
respiratori
muscl
e
mild
hypercapn
encephalopathi
kelli
matthay
score
f
inabl
spontan
clear
airway
excess
secret
express
lowest
score
arbitrari
cough
effici
scale
evalu
nurs
basi
volum
expel
sputum
three
hard
cough
effort
less
ml
ml
ml
patient
divid
two
group
group
case
patient
receiv
medic
treatment
earli
fiberopt
bronchoscopi
within
h
start
non
invas
ventil
group
ii
control
patient
receiv
medic
treatment
non
invas
ventil
patient
receiv
medic
therapi
consist
control
oxygen
therapi
nebul
bronchodil
salbutamol
anticholinerg
drug
intraven
corticosteroid
antibiot
strategi
base
empir
intraven
administr
levofloxacin
plu
blactam
penicillinallerg
patient
levofloxacin
plu
aztreonam
carbapenem
unless
risk
factor
pseudomona
aeruginosa
identifi
ciprofloxacin
plu
antipseudomon
blactam
antibiotictherapi
later
adjust
accord
result
bacteri
cultur
subcutan
lowmolecular
weight
heparin
therapi
comorbid
necessari
anti
stress
ulcer
non
invas
ventil
deliv
pressur
support
ps
mode
posit
endexpiratori
pressur
peep
pressur
control
mode
bipap
via
wellfit
fullfac
mask
addit
heat
humidifi
ps
inspiratori
posit
airway
pressur
ipap
initi
set
cm
h
titrat
achiev
expiratori
tidal
volum
mlkg
respiratori
rate
breath
min
maximum
cm
h
depend
clinic
arteri
blood
gase
abg
respons
patient
toler
peep
expiratori
posit
airway
pressur
epap
alway
set
cm
h
achiev
optim
ventil
oxygen
backup
rr
set
breathsmin
fio
initi
set
titrat
till
reach
arteri
oxygen
satur
rang
time
initi
niv
bronchoscopi
procedur
record
follow
bronchoscopi
patient
remain
noninvas
ventilatori
support
least
two
hour
bronchoscopi
level
consciou
electrocardiogram
arteri
blood
pressur
puls
oximet
ventilatori
paramet
fio
ventil
mode
inspiratori
expiratori
pressur
tidal
volum
respiratori
rate
continu
monitor
arteri
sampl
drawn
blood
ga
analysi
arteri
line
baselin
h
procedur
ventil
set
adjust
optim
ventilatori
support
fraction
inspir
oxygen
fio
increas
throughout
procedur
fob
perform
patient
adapt
nippv
swivel
connector
tadapt
insert
ventil
tube
mask
allow
insert
bronchoscop
sedat
achiev
case
use
midazolam
rang
mg
mg
increment
dose
achiev
consciou
sedat
insert
bronchoscop
repeat
everi
three
five
minut
accord
patient
toler
topic
anesthesia
nasopharynx
lidocain
spray
solut
larynx
ml
lidocain
hydrochlorid
instil
via
bronchoscop
channel
laryng
tracheal
bronchial
mucosa
exceed
overal
dose
mg
perform
advanc
bronchoscop
tracheobronchi
tree
firstli
care
suction
bronchial
secret
perform
fulli
clear
airway
tip
fob
wedg
bronchial
sub
segment
bronchoalveolar
lavag
bal
perform
sequenti
instil
five
aliquot
ml
salin
solut
room
temperatur
retriev
fluid
sent
immedi
microbiolog
laboratori
microscop
analysi
cultur
isol
bacteria
count
cfuml
bal
fluid
consid
etiolog
agent
infect
durat
bronchoscopi
defin
time
insert
remov
bronchoscop
tracheobronchi
tree
bronchoscop
procedur
fio
decreas
order
maintain
arteri
oxygen
satur
measur
puls
oximetri
spo
routin
chest
physiotherapi
done
facilit
expector
electrocardiogram
spo
noninvas
blood
pressur
monitor
continu
abg
sampl
follow
baselin
end
fbo
subsequ
clinic
indic
wean
nippv
appli
continu
least
first
h
clinic
statu
abg
improv
nippv
administ
intermitt
session
last
two
six
hour
three
time
daili
ps
ipap
reduc
progress
nippv
wean
consid
success
within
three
day
ventil
follow
criteria
met
longer
h
breath
oxygen
fio
ph
spo
rr
less
breathsmin
fulli
consciou
effici
cough
signific
amount
sputum
radiograph
improv
chest
infect
stabl
hemodynam
statu
failur
nippv
trial
consid
least
one
follow
criteria
intub
met
cardiac
arrest
sever
hemodynam
instabl
respiratori
arrest
gasp
andor
worsen
abg
worsen
sensorium
level
nippv
comparison
two
group
studi
regard
abg
data
success
nippv
avoid
invas
mechan
ventil
durat
nippv
length
icu
stay
mortal
record
analyz
statist
use
appropri
statist
test
compar
case
control
prospect
studi
conduct
patient
admit
critic
care
medicin
depart
respiratori
intens
care
unit
alexandria
main
univers
hospit
acut
exacerb
chronic
obstruct
pulmonari
diseas
copd
fulfil
criteria
applic
non
invas
posit
pressur
ventil
nippv
patient
randomli
assign
two
equal
group
alloc
random
group
case
patient
receiv
convent
medic
treatment
plu
earli
fiberopt
bronchoscopi
non
invas
ventil
group
ii
control
patient
receiv
convent
medic
treatment
noninvas
ventil
comparison
two
studi
group
accord
arteri
blood
gase
differ
period
admiss
patient
initi
manag
repeat
sit
bronchodil
nebul
face
mask
flow
lmin
ph
group
rang
mean
valu
group
ii
ph
rang
mean
valu
statist
differ
group
p
six
twelv
hour
admiss
niv
bronchoscopi
ph
group
rang
mean
valu
group
ii
ph
rang
mean
valu
signific
statist
differ
group
p
h
admiss
niv
h
bronchoscopi
group
improv
ph
group
rang
mean
valu
significantli
better
valu
group
ii
ph
rang
mean
valu
p
admiss
face
mask
flow
lmin
group
rang
mmhg
mean
valu
mmhg
group
ii
rang
mmhg
mean
valu
mmhg
statist
differ
group
p
six
twelv
hour
admiss
niv
bronchoscopi
group
rang
complic
develop
fob
procedur
desatur
arteri
blood
less
display
monitor
occur
patient
increas
heart
rate
beatsminut
occur
case
ventil
set
fob
among
group
inspiratori
posit
airway
pressur
ipap
fob
rang
cm
h
mean
valu
fob
rang
mean
valu
signific
statist
differ
p
expiratori
posit
airway
pressur
epap
fob
rang
cm
h
mean
valu
fob
significantli
less
rang
mean
valu
p
frequenc
fob
rang
breath
per
minut
mean
valu
significantli
less
fob
rang
mean
valu
p
also
fraction
inspir
oxygen
fio
show
signific
decreas
bronchoscopi
rang
mean
valu
fob
versu
mean
valu
fob
p
outcom
evalu
regard
success
wean
niv
total
durat
niv
succeed
case
length
icu
stay
mortal
rate
hospit
group
case
success
wean
nippv
case
fail
nippv
intub
group
ii
case
success
wean
nippv
case
fail
nippv
intub
signific
statist
differ
favor
group
p
total
durat
niv
succeed
case
group
rang
h
mean
valu
group
ii
rang
h
mean
valu
signific
statist
valu
group
p
regard
length
intens
care
unit
icu
stay
group
rang
day
mean
valu
group
ii
rang
day
mean
valu
signific
statist
valu
group
p
one
case
group
die
versu
case
group
ii
signific
statist
valu
group
p
alert
follow
complex
threestep
command
ie
take
sheet
paper
tear
four
piec
place
three
piec
one
pile
alert
follow
simpl
command
show
two
finger
letharg
arous
follow
simpl
command
stupor
ie
intermitt
follow
simpl
command
even
vigor
attempt
arous
patient
comatos
brain
stem
intact
comatos
brain
stem
dysfunct
tabl
comparison
two
studi
group
accord
index
differ
period
follow
bacteriolog
studi
bal
reveal
growth
case
case
posit
find
staphylococcu
aueru
case
pseudomona
aeuroginosa
found
case
candida
found
case
escherichia
coli
proteu
klebsiella
found
differ
patient
arteri
blood
gase
analysi
show
almost
similar
baselin
ph
mean
valu
group
versu
p
group
ii
rel
improv
ph
notic
similar
pattern
group
applic
nippv
bronchoscopi
mean
valu
ph
group
improv
group
ii
mean
valu
becam
signific
statist
differ
group
p
signific
differ
ph
notic
favor
group
bronchoscopi
mean
valu
ph
significantli
better
valu
group
ii
ph
mean
valu
p
chang
ph
applic
bronchoscopi
compar
studi
done
scala
et
al
ph
initi
improv
applic
nippv
remain
bronchoscopi
improv
significantli
bronchoscopi
p
scala
et
al
studi
first
studi
perform
assess
role
fob
nippv
patient
decompens
copd
main
differ
control
group
studi
patient
invas
mechan
ventil
commun
acquir
pneumonia
etiolog
decompens
studi
group
similar
chang
notic
initi
mean
valu
mmhg
improv
applic
nippv
signific
improv
bronchoscopi
group
group
ii
read
respect
signific
differ
detect
third
read
bronchoscopi
group
nearli
time
group
ii
p
compar
result
scala
et
al
result
observ
similar
two
studi
trend
mmhg
initi
set
nippv
fiberopt
bronchoscopi
respect
oxygen
index
low
group
baselin
mean
valu
group
ii
respect
start
show
improv
group
applic
nippv
signific
improv
oxygen
seen
group
compar
group
ii
bronchoscopi
group
mean
valu
group
versu
group
ii
p
baselin
read
compar
scala
et
al
studi
increas
nippv
contrast
present
studi
drop
bronchoscopi
explain
differ
time
sampl
post
bronchoscopi
two
studi
prefer
postpon
sampl
current
studi
h
post
bronchoscopi
long
signific
drop
oxygen
satur
record
oximetri
avoid
record
immedi
rel
desatur
expect
bronchoscopi
may
mask
real
improv
oxygen
clear
secret
lung
bronchoalveolar
lavag
besid
etiolog
decompens
scala
studi
commun
acquir
pneumonia
studi
differ
factor
includ
upper
lower
respiratori
tract
infect
environment
factor
atopi
discontinu
mainten
medic
treatment
anoth
medic
ill
consid
limit
data
applic
fob
nippv
copd
patient
import
record
complic
relat
fob
group
studi
valid
safeti
procedur
specif
set
compar
overal
rate
fbo
relat
complic
studi
complic
develop
fob
procedur
desatur
arteri
blood
less
display
monitor
occur
patient
clinic
signific
prevent
complet
procedur
temporari
minut
easili
manag
temporari
increas
ps
ipap
nippv
enhanc
procedur
anoth
complic
encount
form
increas
heart
rate
beat
minut
occur
case
mostli
relat
light
sedat
disappear
administr
extra
dose
sed
drug
howev
signific
side
effect
vomit
cardiovascular
event
pneumothorax
bronchospasm
happen
procedur
lack
major
complic
consist
previou
report
clearli
demonstr
feasibl
safeti
fbo
plu
bal
perform
assist
nippv
patient
sever
hypoxem
hypercapn
arf
otherwis
intub
allow
invas
procedur
also
agreement
feasibl
studi
done
han
baumann
et
al
assess
safeti
fob
patient
acut
hypoxem
respiratori
failur
requir
nippv
averag
durat
bronchoscopi
min
rang
min
case
bronchoscopi
complet
without
subsequ
complic
two
patient
develop
transient
valu
procedur
minimum
tabl
applic
fob
group
patient
provid
addit
benefit
apart
drainag
copiou
secret
clear
airway
provis
earli
accur
sampl
tracheal
alveolar
secret
microbiolog
examin
analysi
greatli
help
reach
accur
diagnosi
start
target
antibiot
notic
organ
isol
studi
except
streptococcu
pneumonia
isol
current
studi
although
known
first
caus
organ
commun
acquir
pneumonia
second
common
organ
acut
exacerb
haemophilu
influenza
bacteria
find
might
explain
high
proport
patient
present
studi
initi
admit
hospit
medic
ward
shift
critic
care
area
develop
decompens
respiratori
failur
might
got
gram
neg
hospit
acquir
infect
stay
addit
preced
intak
oral
antibiot
admiss
may
alter
classic
pattern
microorgan
analysi
nippv
set
applic
fob
show
signific
improv
paramet
procedur
form
decreas
epap
ipap
respiratori
rate
fio
tabl
p
valu
paramet
find
demonstr
clear
benefit
fob
synerget
tool
nippv
minim
work
breath
oxygen
requir
subsequ
reflect
form
lower
ventil
set
benefici
effect
mainli
due
clearanc
secret
also
due
recruit
partial
atelectat
alveoli
wash
mucou
plug
group
ii
case
success
wean
nippv
case
fail
requir
intub
mechan
ventil
fail
due
accumul
secret
subsequ
deterior
abg
find
depress
conscious
level
compar
failur
rate
anoth
studi
also
done
raffael
scala
et
al
patient
acut
respiratori
failur
nippv
fail
patient
near
studi
anoth
studi
done
carlucci
et
al
studi
noninvas
versu
convent
mechan
ventil
patient
patient
niv
patient
eventu
requir
endotrach
intub
group
present
studi
failur
rate
nippv
significantli
less
group
ii
patient
fail
patient
scala
et
al
studi
studi
done
assess
effect
earli
fbo
nippv
techniqu
fail
patient
discrep
ratio
two
studi
explain
due
small
number
patient
make
statist
analysi
correl
unreli
besid
etiolog
decompens
scala
studi
commun
acquir
pneumonia
studi
differ
factor
less
medic
seriou
pneumonia
total
durat
niv
succeed
case
group
patient
rang
h
mean
valu
group
ii
patient
rang
h
mean
valu
signific
statist
valu
group
p
denot
possibl
benefici
effect
fob
facilit
faster
wean
remov
secret
improv
blood
gase
durat
nippv
group
ii
less
compar
raffael
scala
et
al
studi
nppv
deliv
median
durat
h
h
mean
durat
first
day
h
sd
h
median
durat
day
anoth
studi
done
carlucci
aetal
mean
length
niv
accord
reason
mechan
ventil
day
rang
day
hypoxem
arf
day
rang
day
hypercapn
arf
day
rang
day
pulmonari
edema
tabl
length
intens
care
unit
icu
stay
group
significantli
shorter
group
compar
group
ii
p
explain
faster
improv
patient
group
less
incid
intub
mechan
ventil
definit
lead
prolong
icu
stay
group
ii
compar
length
icu
stay
group
ii
appli
nippv
without
fob
anoth
similar
match
group
nippv
carlucci
et
al
studi
high
degre
similar
exist
length
stay
present
studi
rang
day
mean
valu
day
day
nippv
group
studi
one
case
group
die
versu
case
group
ii
signific
statist
differ
group
p
compar
mortal
group
mortal
scala
et
al
studi
patient
die
found
much
less
studi
attribut
etiolog
decompens
scala
studi
commun
acquir
pneumonia
studi
differ
factor
less
sever
howev
interpret
data
limit
number
patient
unreli
mortal
group
ii
came
agreement
studi
appli
nippv
hypercapn
respiratori
failur
exampl
mortal
carlucci
et
al
studi
patient
minor
chang
percentag
mortal
differ
studi
understood
light
differ
level
care
experi
differ
center
well
differ
baselin
characterist
studi
group
patient
final
obviou
applic
fob
safe
benefici
patient
present
studi
term
outcom
also
reduc
econom
burden
patient
care
reduc
number
patient
need
invas
mechan
ventil
well
shorter
stay
icu
howev
select
patient
manag
nippv
applic
fbo
benefici
remain
clinic
decis
done
treat
physician
base
overal
clinic
condit
patient
initi
respons
treatment
nippv
also
avail
resourc
skill
physician
provis
fob
minim
risk
complic
applic
random
clinic
trial
role
bronchoscopi
set
ahrf
clear
consensu
precis
guidelin
might
develop
futur
emphas
applic
standard
care
nippv
limit
studi
relat
mainli
limit
sampl
size
patient
case
control
howev
explain
difficult
recruit
patient
fulfil
match
criteria
involv
studi
patient
recruit
period
month
consid
also
novelti
research
first
time
best
knowledg
investig
role
fbo
nippv
aecopd
patient
scala
et
al
studi
publish
compar
two
group
patient
nippv
control
group
scala
et
al
studi
patient
invas
ventil
total
agre
studi
import
pioneer
claim
studi
design
object
reason
result
reach
pilot
studi
consid
preliminari
cornerston
start
point
investig
topic
multicent
studi
provid
adequ
sampl
size
reason
durat
anoth
limit
relat
technic
difficulti
earli
provis
fbo
cours
nippv
plan
procedur
within
first
h
patient
admiss
howev
unavail
skill
personnel
bronchoscopi
safe
way
mani
time
delay
procedur
h
initi
plan
patient
underw
bronchoscopi
later
h
admiss
omit
studi
anoth
studi
done
han
et
al
role
fob
patient
acutehypoxem
respiratori
failur
requir
nippv
median
durat
continu
niv
prior
bronchoscopi
h
last
consid
limit
present
studi
unavail
sed
drug
dexmedetomidin
precedex
egyptian
market
would
definit
better
choic
provid
adequ
safe
sedat
fob
without
compromis
respir
cardiovascular
stabil
patient
howev
provis
titrat
sedat
midazolam
supervis
highli
experienc
intensivist
abl
provid
adequ
sedat
bronchoscopi
seriou
complic
